The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | Real-world data for nivo in recurrent malignant pleural mesothelioma
Robin Cornelissen, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, discusses a real-world analysis of patients with progressive malignant pleural mesothelioma (MPM) receiving nivolumab, an anti-PD-1 monoclonal antibody which showed promising activity in Phase II clinical trials. Patients participating in the BMS-sponsored Expanded Access Program from both the Erasmus Medical Center and The Netherlands Cancer Institute cohorts were included in the analysis. Over 100 patients treated with nivolumab and evaluated via CT were identified. The overall response rate (ORR) and median overall survival (mOS) were found to be lower than those seen in clinical trials of checkpoint inhibitors. In the 10 patients who did achieve a partial response, mOS was significantly improved and no deaths were reported after 14 months of follow up. PD-L1 positivity was found to be associated with an improved ORR and may represent a useful biomarker for nivolumab treatment. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
